HCW Biologics Inc
HCWB
View Detailed Chart
1.040USD
+0.050+5.05%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
2.73MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+5.05%
5 Days
-6.31%
1 Month
-13.33%
6 Months
-76.99%
Year to Date
+7.15%
1 Year
-93.95%
View Detailed Chart
TradingKey Stock Score of HCW Biologics Inc
Currency: USD Updated: 2026-02-06Key Insights
HCW Biologics Inc's fundamentals are relatively weak, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 193 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 8.00.In the medium term, the stock price is expected to trend down.The company has shown weak stock market performance over the past month, in line with its weak fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
HCW Biologics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
HCW Biologics Inc Highlights
StrengthsRisks
HCW Biologics Inc. is a clinical-stage biopharmaceutical company. It is focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation, and age-related diseases, such as cancer, cardiovascular diseases, diabetes, neurodegenerative diseases, autoimmune diseases, as well as other conditions. It has developed a Tissue factOr-Based fusion (TOBI) discovery platform to generate designer, novel multi-functional fusion molecules with immunotherapeutic properties. Its lead product candidates include HCW9218 and HCW9302. HCW9218 is a clinical-stage bifunctional molecule that is designed to impact senescence by reducing senescent cells. The Company is prepared to progress HCW9218 in Phase II clinical trials for non-oncology indications.HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes. Its other product candidates include HCW9201, HCW9206, HCW11-006, and others.
Growing
The company is in a growing phase, with the latest annual income totaling USD 2.57M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 2.57M.
Overvalued
The company’s latest PE is -0.07, at a high 3-year percentile range.
Institutional Buying
The latest institutional holdings are 125.21K shares, increasing 14.47% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 15.43K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.68.
Analyst Rating
Based on
1
analysts
Buy
Current Rating
8.000
Target Price
+708.08%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
HCW Biologics Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
HCW Biologics Inc Info
HCW Biologics Inc. is a clinical-stage biopharmaceutical company. It is focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation, and age-related diseases, such as cancer, cardiovascular diseases, diabetes, neurodegenerative diseases, autoimmune diseases, as well as other conditions. It has developed a Tissue factOr-Based fusion (TOBI) discovery platform to generate designer, novel multi-functional fusion molecules with immunotherapeutic properties. Its lead product candidates include HCW9218 and HCW9302. HCW9218 is a clinical-stage bifunctional molecule that is designed to impact senescence by reducing senescent cells. The Company is prepared to progress HCW9218 in Phase II clinical trials for non-oncology indications.HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes. Its other product candidates include HCW9201, HCW9206, HCW11-006, and others.
Ticker SymbolHCWB
CompanyHCW Biologics Inc
CEOWong (Hing C)
Websitehttps://hcwbiologics.com/
Related Instruments
+3.66%
+3.17%
+0.93%
+1.99%
+1.78%
+1.60%
-0.95%
+4.49%
+2.10%
+10.00%
+2.72%
+4.15%
+1.81%
+4.17%
+0.72%
+1.06%
+2.46%
0.00%
+0.53%
+0.56%Popular Symbols
278.120
+2.210 (+0.80%)
185.410
+13.530 (+7.87%)
69281.380
-688.750 (-0.98%)
282.580
+22.390 (+8.61%)
2067.540
+15.810 (+0.77%)
411.110
+13.900 (+3.50%)
4952.980
+142.360 (+2.96%)
63.303
+0.206 (+0.33%)
1.182
+0.004 (+0.35%)
157.098
+0.057 (+0.04%)
